- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05200676
Cardiac Arrhythmias in Greenland
The study is a phd-study comprising several substudies focusing on cardiac arrhythmias, mainly atrial fibrillation, among Greenlanders in Greenland.
Some previous studies have indicated that the prevalence may be lower than among Westerners, however; studies have also indicated that atrial fibrillation is underdiagnosed.
These studies aim to:
- Estimate the prevalence of AF among Greenlanders in Greenland aged 55 years or older.
- Estimate the prevalence of well-known risk factors among those found to have AF
- Explore the symptoms of those affected by AF in Greenland
- Among part of the participants: estimate the prevalence of autonomic neuropathy as this may cause arrhythmias.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atrial fibrillation (AF) is the most common cardiac arrhythmia globally and a major risk factor for ischemic strokes, transient ischemic attacks, increased morbidity and mortality.
Risk factors for AF include diabetes, hyperthyroidism, hypertension, obesity, ischemic heart disease (IHD), age and gender with men generally having a higher risk of developing AF.
The current prevalence of cardiac arrhythmias in Greenland is unknown. From 1962 to 1964 12-lead electrocardiograms (ECGs) were performed on 181 adults and only one of these showed AF. A more recent study from 2013 estimating the incidence of ischemic strokes among Greenlanders found that five percent of this study-population had been diagnosed with AF before the incident, while 32.4 % were diagnosed after the incident, suggesting that AF may be underdiagnosed. Comparing the age of the patients to data from Denmark, the authors found that the incidence rate for stroke was higher among almost all younger age groups in Greenland.
Previous studies have shown that ethnicity may influence the risk of developing AF. The genetic profile of the Greenlandic Inuit has already been shown to have a major impact on the risk of developing type 2 diabetes.
Regarding other AF-related risk factors, hypertension is common with a prevalence of app. 40% among men and 32% among women based on self-reported data, and a study comparing data from ECGs performed in 1963 with more current data has shown a rise in the incidence of IHD.
Furthermore, the number of obese people in Greenland is steadily rising and between 1963 and 2008, the proportion of obese people (BMI≥30) increased from 4.0% to 33.2% for men and 8.3% to 24.5% for women between 50 to 69 years.
In conclusion, the risk factors for cardiac arrhythmias are increasing in Greenland and the overall aim of this study is to estimate the prevalence, risk factors, mortality, morbidity and treatment of arrhythmias in Greenland.
Relevance: as mentioned above, this study aims to estimate the prevalence, risk factors, mortality, morbidity and treatment of arrhythmias in Greenland, all of which is currently unknown. By doing this, the study aims to not only improve the treatment rate of arrhythmias, but also lower the prevalence of diseases such as strokes, which are often caused by arrhythmias. By lowering this prevalence, some deaths and cases of disability can be prevented. Furthermore, the investigators hope to assess whether arrhythmias are influenced differently by ethnicity and risk factors such as diabetes in Greenland than in Europe and if patients with certain diseases and/or symptoms have a higher risk of developing arrhythmias and should be monitored more closely.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Nadja Albertsen, MD, MSc
- Phone Number: +4531478797
- Email: n.albertsen@rn.dk
Study Contact Backup
- Name: Stig Andersen, MD, PhD
- Phone Number: +4597664182
- Email: lasa@rn.dk
Study Locations
-
-
-
Nuuk, Greenland, 3900
- Ilisimatusarfik
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- At least 50 years old
- Greenlandic ethnicity based on parents' birth place.
- No history of cardiac disease or arrhythmia
Exclusion Criteria:
- Celiac disease (for the SmartPill-study)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Main group
All included in the study will offered to participate in:
|
ePatch registers the heart rate continuously when attached to the chest of the participant.
|
Subgroup
Part of the study-population will be offered to participate in en examination with a SmartPill. The Smartpill measures pressure, pH, temperature and movement in the gut. These measurements gives an indication of the function of the autonomic nervous system (ANS) of the participant. Although measured in the gut, this is relevant as ANS-dysfunction may cause arrhythmias. Only a subgroup of the study population will be offered to participate due to the cost of this examination. |
ePatch registers the heart rate continuously when attached to the chest of the participant.
SmartPill is swallowed and passes through the digestive system while sending information to a recording device.
The pill is passed in the stool and not reused.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence od cardiac arrhythmiaa / atrial fibrillation in the population older than 50 years
Time Frame: Completed within 6 months.
|
Whether participant has an arrhythmia or not - and if the participant does, what kind of arrhythmia.
ePatch recordings will be analysed by the producing company after the completion of the recordings of all participants.
|
Completed within 6 months.
|
Prevalence of common symptoms of arrhythmias
Time Frame: Completed within 8 months
|
Questionnaire-based. Participants will be asked about the most common symptoms of arrhythmias (palpitations, chest pains, feeling a "loss of a beat", dizziness).
Depending on the results, the questionnaires may be followed-up by qualitative interviews.
The questionnaires are filled out as part of the trial.
Results will be entered into a database (RedCap) continuously and analysed after the trial.
|
Completed within 8 months
|
Prevalence of risk factors for AF
Time Frame: Completed within 8 months
|
Questionnaire-based. Participants will be asked about common risk factors for AF (family history, smoking, hypertension, ischemic heart disease, thyroid disease, age, gender).
The questionnaires are filled out as part of the trial.
Results will be entered into a database (RedCap) continuously and analysed after the trial.
|
Completed within 8 months
|
Number of patients with ANS-neuropathy
Time Frame: Within 10 months
|
Based on the recordings of the SmartPill-system.
Data will be analysed externally by the MechSense-group at Aalborg University Hospital.
|
Within 10 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nadja Albertsen, MD, PhD, Aalborg University / University of Greenland and Aalborg University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KVUG 2020-18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on ePatch
-
Yale UniversityWHOOP Inc.; ZS Associates, Inc.Completed
-
Philips Clinical & Medical Affairs GlobalRecruitingSyncope | ArrythmiaFrance, Germany
-
Charite University, Berlin, GermanyNot yet recruitingArrhythmias, Cardiac | Heart Arrest | Electrocardiography